Kendra Lynn Sweet MD

PubMed

• Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.
  Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, Anthony S Stein, David A Rizzieri
  Leukemia & Lymphoma. 2025-03-11
• Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
  Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
  Blood Advances. 2025-02-10
• Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
  Akriti G Jain, Virginia O Volpe, Chen Wang, Somedeb Ball, Katherine Tobon
  Annals of Hematology. 2025-01-01

Journal Articles

• A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease  
  Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
• A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease  
  Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research

Abstracts/Posters

• SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018